Joel Greenblatt Vertex Pharmaceuticals Inc Transaction History

Gotham Asset Management, LLC

$11.5 Billion
Q1 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gotham Asset Management, LLC holds 27,777 shares of VRTX stock, worth $12.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

27,777

Previous 30,111 7.75%

Holding current value

$12.3 Million

Previous $12.1 Million 11.06%

% of portfolio

0.12%

Previous 0.12%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$402.49 - $513.76 $939,411 - $1.2 Million	-2,334 Reduced 7.75%	27,777 $13.5 Million
Q4 2024 Feb 14, 2025	BUY	$396.64 - $516.74 $1.18 Million - $1.54 Million	2,978 Added 10.98%	30,111 $12.1 Million
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $1.11 Million - $1.22 Million	2,422 Added 9.8%	27,133 $12.6 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $2.51 Million - $3.1 Million	6,393 Added 34.9%	24,711 $11.6 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $499,420 - $546,448	1,225 Added 7.17%	18,318 $7.66 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $1.71 Million - $2.05 Million	4,992 Added 41.25%	17,093 $6.95 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $219,140 - $234,874	648 Added 5.66%	12,101 $4.21 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $164,127 - $183,697	-522 Reduced 4.36%	11,453 $4.03 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $3.9 Million - $4.45 Million	-13,765 Reduced 53.48%	11,975 $3.77 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $3.39 Million - $3.82 Million	-11,867 Reduced 31.56%	25,740 $7.43 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $2.41 Million - $2.69 Million	8,791 Added 30.51%	37,607 $10.9 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $313,906 - $390,846	1,336 Added 4.86%	28,816 $8.12 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.05 Million - $1.23 Million	4,725 Added 20.76%	27,480 $7.17 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $440,400 - $555,943	2,488 Added 12.28%	22,755 $5 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $2.91 Million - $3.26 Million	-16,038 Reduced 44.18%	20,267 $3.68 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $6.81 Million - $8.03 Million	36,305 New	36,305 $7.32 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $316,104 - $421,589	-1,527 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $2,045 - $2,424	-8 Reduced 0.52%	1,527 $416,000
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $100,789 - $132,222	-447 Reduced 22.55%	1,535 $446,000
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $168,805 - $209,399	845 Added 74.32%	1,982 $472,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $10 Million - $13.5 Million	-60,130 Reduced 98.14%	1,137 $249,000
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $9.89 Million - $11.1 Million	59,466 Added 3301.83%	61,267 $10.4 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $296,462 - $342,856	1,801 New	1,801 $330,000
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $2.18 Million - $2.54 Million	-14,974 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $1,516 - $1,771	-10 Reduced 0.07%	14,974 $2.44 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $13.1 Million - $14.9 Million	-95,516 Reduced 86.44%	14,984 $2.25 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $16.4 Million - $17.9 Million	110,500	110,500 $16.8 Million

Others Institutions Holding VRTX

# of Institutions

1,832

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $114B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account